Effron MB, et al. - In a real-world setting of acute coronary syndrome (ACS)-percutaneous coronary intervention (PCI) patients treated with ticagrelor vs prasugrel, it was observed, on retrospective analysis, that prasugrel was preferred over ticagrelor in younger patients with lower risk of bleeding or comorbidities. Furthermore, prasugrel-associated clinical outcomes were found to be noninferior to those associated with ticagrelor, after propensity matching.